IRVINE, CA--(Marketwired - Apr 19, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is set to participate in the Global Health Catalyst (GHC) Summit at Harvard Medical School on April 28-30, 2017. Information on the GHC Summit is available at http://www.globalhealthcatalystsummit.org.
The Cannabis Science Versus Cancer and Other Malignancies and the Palliative Care and Mental Health Sessions will be live-streamed to an audience worldwide. Those interested in joining the live-streaming of these sessions, as well as any of the other GHC Summit sessions, can subscribe to the Next Generation Global Health Security Network YouTube Channel at https://www.youtube.com/channel/UCqihIfrETTl2eRMxNQxUCDQ. Additionally, the recorded sessions can be accessed via this YouTube channel.
As previously announced, Mr. Dabney will be the keynote speaker and a panelist for the Cannabis Science Versus Cancer and Other Malignancies Session. The theme for this session is "Medical Cannabis in Global Health," and speakers and panelists will provide updates on leading-edge collaborations investigating the use of medical cannabis in the treatment of cancer and other malignancies, and closing the global pain divide. Information on this session is available at https://www.globalhealthcatalystsummit.org/medical-cannabis.
"I look forward to CBIS' participation in the GHC Summit, as this important event will provide CBIS with access to a global audience of stakeholders involved in the research, development, and trials of medicines to treat cancer and cancer symptoms," stated Mr. Dabney.
CBIS' CMO, Dr. Herman, will also participate in the Palliative Care and Mental Health Session. Dr. Herman will deliver a presentation based on his analysis of the global health divide. This session will address advances in global palliative care, closing the pain divide, psycho-oncology, and mental health disparities.
"The GHC Summit will provide CBIS with a global platform to advance our relationship with the Dana-Farber Cancer Institute, as well as with other individuals and organizations. Given CBIS' Collaborative Research Agreement (CRA) with Dana-Farber, we are excited about the potential to jointly investigate and develop use of cannabinoids to treat various forms of cancers," stated Dr. Herman.
Information on this session is available at:
https://www.globalhealthcatalystsummit.org/agenda and http://www.huffingtonpost.com/felicia-m-knaul/closing-the-global-pain-divide_b_3963838.html.
In addition to Mr. Dabney's and Dr. Herman's respective presentations, the Cannabis Science Session will feature a number of distinguished speakers, including Dr. Wil Ngwa, the Director of the GHC Program at the Dana-Farber/Harvard Cancer Center; Dr. Roscoe M. Moore, Jr., former Assistant U.S. Surgeon General, Interim Chairman of the Board of the Constituency for Africa (CFA), and Chairman of CBIS' Scientific Advisory Board; the Honorable Ronald V. Dellums, former Member of the U.S. Congress, former Mayor of Oakland, CA, and Chairman of CBIS' International Government Affairs Board; Mr. Melvin P. Foote, President & CEO of CFA; and Dr. Dr. Allen Herman, CBIS' Chief Medical Officer (CMO). This session will be moderated by the Honorable Donna Christensen, former Member of the U.S. Congress, and Chairperson of the Congressional Black Caucus Health Braintrust.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.